FOXM1 and acute lymphoblastic leukemia: A variety of molecularly targeted chemo-sensitization approaches of this sort are pursued in myeloma [45] – all attempting to build on findings in B-ALL that demonstrate that drug resistance in malignant B lymphocytes may be overcome by suppression of FOXM1 [46].